MaxCyte Statistics
Total Valuation
MaxCyte has a market cap or net worth of $113.53 million. The enterprise value is $29.14 million.
| Market Cap | 113.53M |
| Enterprise Value | 29.14M |
Important Dates
The last earnings date was Tuesday, November 10, 2026, before market open.
| Earnings Date | Nov 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MaxCyte has 103.21 million shares outstanding. The number of shares has decreased by -0.14% in one year.
| Current Share Class | 103.21M |
| Shares Outstanding | 103.21M |
| Shares Change (YoY) | -0.14% |
| Shares Change (QoQ) | -3.07% |
| Owned by Insiders (%) | 1.25% |
| Owned by Institutions (%) | 56.14% |
| Float | 93.72M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.30 |
| Forward PS | 3.34 |
| PB Ratio | 0.75 |
| P/TBV Ratio | 0.76 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 0.85 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.83, with a Debt / Equity ratio of 0.11.
| Current Ratio | 7.83 |
| Quick Ratio | 7.12 |
| Debt / Equity | 0.11 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -16.90% and return on invested capital (ROIC) is -10.03%.
| Return on Equity (ROE) | -16.90% |
| Return on Assets (ROA) | -9.27% |
| Return on Invested Capital (ROIC) | -10.03% |
| Return on Capital Employed (ROCE) | -17.64% |
| Weighted Average Cost of Capital (WACC) | 10.78% |
| Revenue Per Employee | $377,736 |
| Profits Per Employee | -$307,495 |
| Employee Count | 91 |
| Asset Turnover | 0.17 |
| Inventory Turnover | 0.87 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -25.17% in the last 52 weeks. The beta is 1.48, so MaxCyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.48 |
| 52-Week Price Change | -25.17% |
| 50-Day Moving Average | 1.26 |
| 200-Day Moving Average | 1.07 |
| Relative Strength Index (RSI) | 37.06 |
| Average Volume (20 Days) | 1,501,569 |
Short Selling Information
The latest short interest is 1.83 million, so 1.77% of the outstanding shares have been sold short.
| Short Interest | 1.83M |
| Short Previous Month | 1.09M |
| Short % of Shares Out | 1.77% |
| Short % of Float | 1.95% |
| Short Ratio (days to cover) | 1.81 |
Income Statement
In the last 12 months, MaxCyte had revenue of $34.37 million and -$27.98 million in losses. Loss per share was -$0.26.
| Revenue | 34.37M |
| Gross Profit | 27.84M |
| Operating Income | -29.38M |
| Pretax Income | -27.98M |
| Net Income | -27.98M |
| EBITDA | -25.41M |
| EBIT | -29.38M |
| Loss Per Share | -$0.26 |
Balance Sheet
The company has $101.28 million in cash and $16.89 million in debt, with a net cash position of $84.39 million or $0.82 per share.
| Cash & Cash Equivalents | 101.28M |
| Total Debt | 16.89M |
| Net Cash | 84.39M |
| Net Cash Per Share | $0.82 |
| Equity (Book Value) | 150.93M |
| Book Value Per Share | 1.46 |
| Working Capital | 108.76M |
Cash Flow
In the last 12 months, operating cash flow was -$21.03 million and capital expenditures -$424,000, giving a free cash flow of -$21.45 million.
| Operating Cash Flow | -21.03M |
| Capital Expenditures | -424,000 |
| Depreciation & Amortization | 3.97M |
| Net Borrowing | n/a |
| Free Cash Flow | -21.45M |
| FCF Per Share | -$0.21 |
Margins
Gross margin is 80.98%, with operating and profit margins of -85.47% and -81.40%.
| Gross Margin | 80.98% |
| Operating Margin | -85.47% |
| Pretax Margin | -81.40% |
| Profit Margin | -81.40% |
| EBITDA Margin | -73.92% |
| EBIT Margin | -85.47% |
| FCF Margin | n/a |
Dividends & Yields
MaxCyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | 0.14% |
| Shareholder Yield | 0.14% |
| Earnings Yield | -24.00% |
| FCF Yield | -18.89% |
Analyst Forecast
The average price target for MaxCyte is $4.11, which is 273.36% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $4.11 |
| Price Target Difference | 273.36% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (3Y) | 10.72% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 4 |